Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

Long-lasting control is rarely achieved with tyrosine kinase inhibitors (TKI) alone in metastatic renal cell carcinoma (mRCC). Our study aimed to investigate the survival outcomes of adding stereotactic body radiotherapy (SBRT) to TKI in mRCC. MATERIALS AND METHODS: From September 2015 to September...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Clin Oncol
Main Authors: He, Liru, Liu, Yang, Han, Hui, Liu, Zhuowei, Huang, Sijuan, Cao, Wufei, Liu, Boji, Qin, Zike, Guo, Shengjie, Zhang, Zhiling, Lin, Maosheng, Jiang, Xiaobo, Lin, Chengguang, Li, Yonghong, Yao, Kai, Dong, Pei, Zhou, Fangjian
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Original Articles: Genitourinary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922069/
https://ncbi.nlm.nih.gov/pubmed/31651452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados